Development and Validation of Analytical Method for Bromhexine Hydrochloride, Chlorpheniramine
Maleate and Guaifenesin by
Simultaneous Equation Spectroscopic Method
Ladmeera1*, Hasumati Raj2, Vineet Jain2
1Research Scholar
2014, Gujarat Technological
University, Gujarat
2QualityAssurance
Department, Shree Dhanvantary
Pharmacy College,
Kim, Surat
*Corresponding Author E-mail: meeralad235@gmail.com
ABSTRACT:
A simple, accurate and precise
spectroscopic method was developed for simultaneous estimation of Bromhexine hydrochloride, Chlorpheniramine
maleate and Guaifenesin in
syrup using simultaneous equation Method. In this spectroscopic method, 249.00
nm and 261.00 nm and 274.00 nm wavelengths respectively were selected for
measurement of slope and intercept according to its calibration curves. Bromhexine, Chlorpheniramine maleate and Guaifenesin show
linearity in a concentration range of 02-10μg/ml, 01-05μg/ml and
25-125μg/ml at their respective λ max. Accuracy, precision and
recovery studies were done by QC samples covering lower, medium and high
concentrations of the linearity range. The relative standard deviation for
accuracy, precision studies were found to be within the acceptance range
(<2%). The limit of determination was 0.102μg/ml, 0.169μg/ml and
0.312μg/ml for Bromhexine, chlorpheniramine
maleate and guaifenesin
respectively. The limit of quantification was
0.311μg/ml, 0.947μg/ml and 0.514μg/ml for Bromhexine,
chlorpheniramine maleate
and guaifenesin respectively. Recovery of Bromhexine, guaifenesin and chlorpheniramine maleate were
found to be 100.02 %, 101.17 and 100.66% respectively confirming the accuracy
of the proposed method. The proposed method is recommended for routine analysis
since they are rapid, simple, accurate and also sensitive and specific by no
heating and no organic solvent extraction.
KEYWORDS: Bromhexine
hydrochloride, Guaifenesin, Chlorpheniramine
maleate, simultaneous estimation, Simultaneous
equation method, analysis method.
INTRODUCTION:
Bromhexine HCl (BRH) is a mucolytic agent used in the treatment of respiratory
disorders associated with viscid or excessive mucus. Bromhexine
depolymerises muco-polysaccharides
directly as well as by liberating lysosomal enzyme
network of fibres in tenacious sputum is broken.[1]
Figure1: Structure of Bromhexine(3)
Guaifenesin may act as an irritant to gastric vagal receptors, and recruit efferent parasympathetic
reflexes that cause glandular exocytosis of a less
viscous mucus mixture. Cough may be provoked. Guaifenesin
increases fluid and mucus removal from the upper respiratory tract by
increasing the volume of secretion and reducing their adhesiveness and surface
tension.
Figure2: Structure of Guaifenesin(3)
Chlorphenamine or chlorpheniramine,
commonly marketed in the form of chlorpheniramine maleate, is a first-generation alkylamine
antihistamine used in the prevention of the symptoms of allergic conditions
such as rhinitis and urticaria. Chlorpheniramine
competes with histamine for H1 receptor sites, there by antagonizing
many histamine effects to reduce allergy signs and symptoms. So, it ultimately reduce the cough.
Figure 3: Structure of Chlorpheniramine
maleate(3)
The review of literature regarding quantitative analysis
of Bromhexine, Guaifenesin
and Chlorpheniramine maleate
revealed that no attempt was made to develop analytical methods for these three drugs. Some
spectrometric methods and chromatographic methods have been reported for the estimation
of the individual drugs.[6-44]The focus of the present study was to
develop and validate a rapid, stable, specific, and economic spectroscopic
method for the estimation of Bromhexine, Guaifenesin and Chlorpheniramine maleate in Syrup.
MATERIALS AND METHODOLOGY:
·
Bromhexine
HCl was gifted by Galpha
Laboratories Ltd., Ankleshwar.
·
Chlorpheniramine Maleate was gifted by Maharshee Laboratories Pvt. Ltd., Bharuch.
·
Guaifenesin
was gifted by Pan Drugs Limited, Nandesari.
·
A double beam UV/Visible spectrophotometer (Shimadzu model
2450, Japan) with spectral width of 2 nm, 1 cm quartz cells was used to measure
absorbance of all the solutions.
·
Spectra were automatically obtained by UV-Probe system
software.
·
An analytical balance (Sartorius CD2250, Gottingen,
Germany) was used for weighing the samples.
·
Sonicator (D120/2H,
TRANS-O-SONIC)
·
Class ‘A’ volumetric glassware were used (Borosillicte)
Standard Solution:
Preparation of the Stock
Solution of Bromhexine HCl:
An accurately weighed quantity of Bromhexine
HCl (10 mg) was transferred to a separate 100 ml
volumetric flask and dissolved and diluted to the mark with Methanol to obtain
standard solution having concentration of Bromhexine
(100μg/ml). Sonicate for 10 mins
if require.
Preparation
of the Stock Solution of Chlorpheniramine Maleate:
An accurately weighed quantity of Chlorpheniramine Maleate (10 mg)
was transferred to a separate 100 ml volumetric flask and dissolved and diluted
to the mark with Methanol to obtain standard solution having concentration of Chlorpheniramine Maleate
(100μg/ml). Sonicate for 10 mins
if require.
Preparation
of the Stock Solution of Guaifenesin:
An accurately weighed quantity of Guaifenesin (15 mg) was transferred to a separate 100 ml
volumetric flask and dissolved and diluted to the mark with Methanol to obtain
standard solution having concentration of Guaifenesin
(150μg/ml). Sonicate for 10 mins
if require.
Preparation of Test Solution:
From the stock solution of BROM take 0.4ml and from stock solution of CHL
take 0.2ml and from the stock solution of GUA take 3.33ml transferred in to
10ml volumetric flask and
diluted up to mark with methanol to give a solution having strength of BROM was
4μg/ml, CHL was 2μg/ml and GUA was 50μg/ml.
Calibration curves for Bromhexine HCl:
Pipette out 0.2, 0.4, 0.6, 0.8and 1.0 ml of the stock solution of Bromhexine
(100μg/ml), , 0.1 ml,
0.2 ml, 0.3 ml, 0.4 ml, 0.5 ml stock solution
of Chlorpheniramine maleate
(100μg/ml) and 1.66 ml,
3.33 ml, 5.0 ml, 6.66 ml, 8.33 ml stock solution
of Guaifenesin (150μg/ml)into a series of 10ml
volumetric flasks and the volume was adjusted to mark with methanol and
measured absorbance at 249.00nm, 261nm and 274 nm. Plot the graph of absorbance
versus respective concentration of Irbesartan and atorvastatin.
Linearityrange of BROM, CHL and GUA was found with
correlation co-efficient.
Development and validation of spectroscopic simultaneous
equation method:
Selection of
wavelength and
Method Development
For determination
of Bromhexine
Hydrochloride, Chlorpheniramine Maleate
and Guaifenesin:
The standard solution of BROM,
CHL and GUA were scanned
separately
between 200-400nm,
and BROM showed absorbance
maxima
at 249.00 nm and CHL at 261.00 nm
and GUA at 274.00 nm (figure 4)
Figure 4: Overlain linear
zero order spectra of BRO (Green), CHL (Violet), GUA (Brown) in 2:1:25 ratio,
respectively
The concentrations of three drugs are
calculated using the following equations:
Where:
Sx, Sy
and Sz are the slops of drugs X, Y and Z
in their calibration curves:
A1*,A2* and A3* are the modified
Absorbance
A1* = A1
– (Ix1 + Iy1 + Iz1)
A2* = A2
– (Ix2 + Iy2 + Iz2)
A3* = A3
– (Ix3 + Iy3 + Iz3)
A1,A2 and A3 are the Absorbance of test
at λ1, λ2 and λ3
respectively
Ix, Iy and Iz are the Intercepts of drugs X, Y and Z in
their calibration curves
Table 1: Calibration
data
for BROM, CHL and GUA at249.00 nm
and 261.00 nm and 274.00 nm respectively. *(n=6)
|
Sr no. |
Brom |
Chlor |
Gua |
Abs. ± SD (n=6) |
||
|
Brom (248 nm) |
Chlor (261nm) |
Gua (274nm) |
||||
|
1 |
2 |
1 |
25 |
0.108 ±0.0083 |
0.016 ±0.0051 |
0.211 ±0.0009 |
|
2 |
4 |
2 |
50 |
0.196 ±0.0021 |
0.037 ±0.0020 |
0.477 ±0.0020 |
|
3 |
6 |
3 |
75 |
0.286 ±0.0021 |
0.0535 ±0.0005 |
0.717 ±0.0013 |
|
4 |
8 |
4 |
10 |
0.366 ±0.0016 |
0.071 ±0.0075 |
0.932 ±0.0012 |
|
5 |
10 |
5 |
125 |
0.457 ±0.0018 |
0.0945 ±0.0010 |
1.190 ±0.0013 |
Table 2: Intraday
and Interday precision data for estimation of BROM, CHL and GUA*(n=3)
|
Drug |
Concentration (ppm) |
Precision Mean ± %RSD |
|
|
Intraday |
Interday |
||
|
Bromhexine HCl |
02 |
0.181 ± 0.317 |
0.183 ± 0.546 |
|
04 |
0.373 ± 0.309 |
0.376 ± 0.405 |
|
|
06 |
0.525 ± 0.190 |
0.525 ± 0.290 |
|
|
Chlorpheniramine Maleate |
01 |
0.252 ± 0.604 |
0.183 ± 0.821 |
|
02 |
0.425 ± 0.489 |
0.376 ± 0.405 |
|
|
03 |
0.622 ± 0.092 |
0.426 ± 0.590 |
|
|
Guaifenesin |
25 |
0.432 ± 0.266 |
0.434 ± 0.351 |
|
50 |
0.653 ± 0.306 |
0.653 ± 0.233 |
|
|
75 |
0.944 ± 0.266 |
0.945 ± 0.161 |
|
Validation parameters:(45)
1. Linearity
and Range:
The Zero order (fig.4) showed linear absorbance at 249.00 nm for BROM (02-10 µg/ml), 261.00 nm for CHL (01-05µg/ml) and 274 nm for GUA (25-125µg/ml) with
correlation Coefficient
(r2) of 0.9997, 0.9959 and 0.9988for BROM, CHL and GUA, respectively.
(figure 5, 6 and 7) This method obeyed
beer’s law in the concentration range
02-10µg/ml, 01-05µg/ml and
25-125µg/ml for BROM, CHL and GUA respectively.
(Table 1)
Figure 5: Calibration curve
for BROM at 249.00 nm
Figure 6: Calibration curve
for CHL at 261.00 nm
2. Precision:
I. Intraday
Precision:
The
precision of the developed method was assessed by analysing
samples of the same batch in nine determinations with three Standard solutions
containing concentrations 1, 2, 3μg/ml for Chlorpheniramine
Maleate 2, 4, 6μg/ml for Bromhexine
HCl and 25, 50, 75μg/ml for Guaifenesin. Three replicate (n=3) each on same day.It presented
in Table 2. These% RSD
value was found to be less than ±2.
0 indicated that the method is precise.
Figure7: Calibration
curve for
GUA at 274.00 nm
II. Interday Precision:
The precision of the developed method was assessed by analysing samples of the same batch in nine determinations
with three Standard solutions containing concentrations 1, 2, 3 μg/ml for Chlorpheniramine Maleate, 2, 4,
6μg/ml for Bromhexine HCl
and 25, 50, 75 μg/ml for Guaifenesin.
Triplicate (n=3) per day for consecutive 3 days for inter-day precision. Interday
precision data presented
in Table 2. These % RSD value
was found to be less than ±2.0indicated that the method is precise.
3. Accuracy:
Accuracy of the method was determined by
recovery study from
syrup at three level
(80%, 100%, 120%)of standard addition.
The% recovery
values are tabulated in Table 3, 4and
5 Percentage recovery
for BROM, CHL and GUA by this method was found in the range
of 99.77-100.05%, 99.50-102.22% and99.42-102.27%,
respectively, the value
of %
RSD within the limit indicated that the method is accurate
and percentage
recovery shows
that there is no interference
from the excipients.
4. Limit of
Detection and Quantitation:
The LOD for BROM, CHL and GUA was
conformed to be 0.1026 µg/ml, 0.1696 µg/ml and
0.3126 µg/ml, respectively.
The LOQ for BROM, CHL and GUA was
conformed to be 0.3110 µg/ml,
0.5141 µg/mland 0.9473 µg/ml, respectively. The obtained LOD
and LOQ results are
presented in Table 6
5.
Robustness and Ruggedness
The obtained Ruggedness and Robustness results are presented
in table 7 The % R.S.D was found to be 0.21- 0.83 %
for BROM, 0.23- 0.46 % for CHL and 0.11 – 0.35 % for GUA. These %RSD value was found to be less than ±
2.0 indicated that the method is precise. No significant changes in
the spectrums were observed, proving that the developed method is rugged
and robust.
Table 3: Recovery
data of BRO*(n=3)
|
Conc. Of BRO from
formulation
(µg/ml) |
Amount of Std. BRO added
(µg/ml) |
Total amount
of BRO (µg/ml) |
Total amount
of BRO found (µg/ml)* Mean± SD |
% Recovery
(n=3) |
% RSD BRO |
|
2 |
1.6 |
3.6 |
3.62±0.0005 |
100.55 |
0.18 |
|
2 |
2.0 |
4.0 |
3.99±0.0005 |
99.78 |
0.17 |
|
2 |
2.4 |
4.4 |
4.39±0.0005 |
99.77 |
0.16 |
Table 4: Recovery
data of CHL*(n=3)
|
Conc. of CHL from
formulation
(µg/ml) |
Amount of Std. CHL added
(µg/ml) |
Total amount
of CHL(µg/ml) |
Total amount
of CHL found (µg/ml)* Mean± SD |
% Recovery
(n=3) |
% RSD CHL |
|
1 |
0.8 |
1.8 |
1.82±0.0005 |
102.22 |
0.13 |
|
1 |
1.0 |
2.0 |
1.98±0.0005 |
99.50 |
0.13 |
|
1 |
1.2 |
2.2 |
2.18±0.0005 |
101.81 |
0.12 |
Table 5: Recovery
data of GUA*(n=3)
|
Conc. of GUA from
formulation
(µg/ml) |
Amount of Std. GUA added
(µg/ml) |
Total amount
of GUA (µg/ml) |
Total amount
of GUA found (µg/ml)* Mean± SD |
% Recovery
(n=3) |
% RSD GUA |
|
25 |
20 |
45 |
44.74±0.001 |
99.42 |
0.51 |
|
25 |
25 |
50 |
50.14±0.001 |
100.29 |
0.29 |
|
25 |
30 |
55 |
56.25±0.005 |
102.27 |
0.15 |
Table 6 LOD and LOQ data of BROM, CHL and GUA *(n=10)
|
Conc. (μg/ml) |
BRO(249.0 nm) (n=10) |
CHL(261.0 nm) (n=10) |
GUA(274.0 nm) (n=10) |
|||||
|
DEX |
CHL |
GUA |
Avg. ± SD |
%RSD |
Avg. ± SD |
%RSD |
Avg. ± SD |
%RSD |
|
2 |
1 |
25 |
0.181
±0.0013 |
0.744 |
0.252
±0.0009 |
0.386 |
0.432
±0.0009 |
0.212 |
|
LOD(μg/ml) |
0.1026 |
0.1696 |
0.3126 |
|||||
|
LOQ(μg/ml) |
0.3110 |
0.5141 |
0.9473 |
|||||
Table 7:
Robustness and Ruggedness data of BROM, CHL and GUA *(n=3)
|
Drugs |
Concentration |
Mean ±% RSD |
|
|
Instrument I |
Instrument II |
||
|
Bromhexine HCl |
02 |
0.181 ± 0.635 |
0.182 ± 0.836 |
|
04 |
0.371 ± 0.410 |
0.372 ± 0.410 |
|
|
06 |
0.525 ± 0.219 |
0.526 ± 0.290 |
|
|
Chlor-pheniramine Maleate |
01 |
0.250 ± 0.460 |
0.251 ± 0.229 |
|
02 |
0.426 ± 0.234 |
0.427 ± 0.468 |
|
|
03 |
0.621 ± 0.245 |
0.623 ± 0.245 |
|
|
Guaifenesin |
25 |
0.433 ± 0.133 |
0.434 ± 0.351 |
|
50 |
0.651 ± 0.177 |
0.652 ± 0.234 |
|
|
75 |
0.942± 0.122 |
0.944 ± 0.323 |
|
|
|
|
|
|
|
Drugs |
Concentration |
Change in Wavelength (249 ± 0.2 nm, 261 ± 0.2 nm, 274 ± 0.2 nm) Mean ±% RSD |
|
|
Wavelength 249.20 nm |
Wavelength 248.80 nm |
||
|
Bromhexine HCl |
02 |
0.182 ± 0.837 |
0.183 ± 0.833 |
|
04 |
0.371 ± 0.411 |
0.372 ± 0.819 |
|
|
06 |
0.524 ± 0.397 |
0.524 ± 0.190 |
|
|
|
|
261.20 nm |
260.80 nm |
|
Chlorpheniramine Maleate |
01 |
0.252 ± 0.604 |
0.254 ± 0.988 |
|
02 |
0.424 ± 0.271 |
0.425 ± 0.359 |
|
|
03 |
0.621 ± 0.161 |
0.623 ± 0.424 |
|
|
|
|
274.20 nm |
273.80 nm |
|
Guaifenesin |
25 |
0.433 ± 0.230 |
0.434 ± 0.479 |
|
50 |
0.652 ± 0.234 |
0.653 ± 0.306 |
|
|
75 |
0.942 ± 0.162 |
0.944 ± 0.105 |
|
Application of the proposed method for analysis of BROM,
CHL and GUAIN combined capsule dosage form:
·
Pipette
out 5 ml of liquid sample, Add 10 ml of methanol, basify with 10 ml 1 M NaOH solution.
·
Extract
with 10 ml chloroform 4 times. Combine chloroform and evaporate.
·
Take
all residue in 20 ml methanol and make the volume upto 100 ml.
·
Finally,
measure absorbance at 249.0 nm, 261.0 nm and 274.0 nm.
·
Determine
the concentration of drugs using equation
|
Drugs |
% Assay ± % RSD(n=3) |
IP Limit |
Bromhexine HCl
|
100.83 ± 0.0010 |
98.5-101.5% |
|
Chlorpheniramine Maleate |
100.50 ± 0.0005 |
98.0-101.0% |
|
Guaifenesin |
100.46 ± 0.0058 |
98.0-101.5% |
Summary of validation parameter:
Table 8: Summary of validation parameters
|
Parameter |
Bromhexine HCl |
Chlorpheniramine Maleate |
Guaifenesin |
|
λmax |
249.0 nm |
261.0 nm |
274.0 nm |
|
Linearity |
2 – 10 ppm |
1 – 5 ppm |
25 – 125 ppm |
|
Regression equation |
y = 0.043x + 0.0223 |
y = 0.0189x – 0.0022 |
y = 0.0097x - 0.0183 |
|
Correlation coefficient (r2) |
0.9997 |
0.9959 |
0.9988 |
|
Accuracy |
100.02 ± 0.628 |
101.17 ± 1.466 |
100.66 ± 1.460 |
|
LOD (n=10) |
0.1026 ppm |
0.1696 ppm |
0.3126 ppm |
|
LOQ(n=10) |
0.3110 ppm |
0.5141 ppm |
0.9473 ppm |
|
Precision Intra-day(n=3) Inter-day
(n=3) |
%RSD 0.190
– 0.317 0.290
– 0.546 |
%RSD 0.092
– 0.604 0.321
– 0.821 |
%RSD 0.266
– 0.306 0.161
– 0.351 |
|
Assay |
100.833 ± 0.001% |
100.50 ± 0.0005% |
100.46 ± 0.005% |
|
Robustness(%RSD) |
0.219 – 0.836% |
0.234 – 0.468 % |
0.122– 0.351 % |
CONCLUSION:
A new, Simultaneous Equation method has been developed for
estimation of Bromhexine hydrochloride, Chlorpheniramine maleate and Guaifenesin in syrup. The method was validated by
employment of ICH(18) guidelines. The validation data
is indicative of good precision and accuracy, and prove the reliability of the
method.
REFERANCE:
1.
Tripathi KD.
Essentials of Medical Pharmacology; 6thEdn; Jaypee
Brothers Medical Publishers (P) Ltd, 2008, pp 213-215.
2.
Lad MV, Jain V, Raj HA, “A review
of analytical methods for determination bromhexine
hydrochloride in pharmaceutical and biological samples.” Pharmatutor, 2014, 2, 35-41.
3.
DrugBank, “Open
Data Drug and Drug Target Database”, DB09019 Bromhexine
Hydrochloride, DB01114 Chlorpheniramine, DB00874 Guaifenesin”, Oct 2013, www.drugbank.ca/drugs.html.
4.
ChemicalBook,www.chemicalbook.com/ProductChemicalPropertiesCB3249453_
EN.htm#MSDS.
5.
Jones and
Bartlett Learning. Nurse’s Drug Handbook; 10thEdn; Jones and
Bartlett Learning International, London, 2011,pp 301,
493.
6.
Susmitha K, Thirumalachary M and Venkateshwarlu
G, “Spectrophotometric determination of Bromhexine hcl in pure and pharmaceutical forms.” Int. Scholarly Res. Notices Ana. Chem.2013, 5, 1-7.
7.
Liu Suying FS and Wong Kwok TX,
“Bromhexine hydrochloride film content on high
performance liquid chromatography.” Res.
Papers Center. 2012, 12,
56-57.
8.
Mehran J,
Mohammad HN and Behrouz A, “Molecularly imprinted
solid-phase extraction for the selective determination of Bromhexine
in human serum and urine with high performance liquid chromatography.” Talanta. 2009, 80, 133-138.
9.
EEndang S and Gunawan I, “TLC densitometric determination of Bromhexine hydrochloride in pharmaceuticals and its
validation.” J. Liq. Chrom.and
Related Tech.2005, 27,
2047-2056.
10.
Rao Monica RP,
Kumar M, Aghav S and Sukre Girish, “Development and validation of HPTLC method for
determination of Bromhexine hydrochloride in human
plasma.” Res. J. Pharm. and Tech.2012, 5, 1054-1057.
11.
Wen Z, Fang F
and Ya Wang, “Bioequivalence study of Bromhexine by liquid chromatography–electrospray
ionization-mass spectrometry after oral administration of Bromhexine
hydrochloride tablet.” J. P’ceuticaland Biomed. Ana.2008, 48, 1206-1210.
12.
Dhoka MV, Gawande VT and Joshi PP, “Simultaneous estimation of
Amoxicillin trihydrate and Bromhexine
hydrochloride in oral dosage forms by spectrophotometric method.” Int. Res. J.
Pharm. 2011, 2,
197-201.
13.
Tantishaiyakul V, Poeaknapo C, Sribun P and Sirisuppanon K, “Simultaneous determination of Dextromethorphan HBr and Bromhexine hcl in tablets by
first-derivative spectrophotometry.” J. P’ceuticaland Biomed. Ana.1997, 17, 237-243.
14.
Mevada D, Bhalodiya K, and Faldu S,
“Development and validation of first order derivative spectrophotometric method
for simultaneous estimation of Bromhexine
hydrochloride and Phenylephrine hydrochloride in
their combined pharmaceutical dosage form.” Pharmatutor. 2014, 2, 132-138.
15.
Amit K and Sanju N, “A validated high performance liquid
chromatographic method for estimation of Bromhexine
and Terbutaline in bulk and tablet dosage forms.” Int. J.
ChemTech Res. 2011,
2, 218-222.
16.
Lalit VS and Sanjaykumar BB, “Development and validation of RP-HPLC
method for the simultaneous estimation of Amoxicillin trihydrate
and Bromhexine hydrochloride from oily suspension.” P’ceutical Ana. Acta.
2010,1,
107.
17.
Satyanarayana PV, Murali M and Venkateswara RP,
“Simultaneous determination of Terbutaline and Bromhexine in combined pharmaceutical dosage form by
RP-HPLC method.” Int. J. ChemTech Res.2012,
4, 240-246.
18.
Shujuan L, Liang
Z, Xia L, Feng Z and Shengxiang
J, “Simultaneous determination of Bromhexine HCl and Baicalin in chinese compound medicine by a reversed-phase ion-pair HPLC.”J.
Food and Drug Ana. 2004,
12, 306-310.
19.
Pai PN, Rao GK, Murthy MS, Agarwal A and Puranik S, “Simultaneous determination of Salbutamol sulphate and Bromhexine
hydrochloride in tablets by reverse phase liquid chromatography.” Ind. J.
P’ceutical Sci.2009, 71, 53–55.
20.
Venkata R, Ramana R, Raghuveer S and Khadgapathi P, “Gas-liquid chromatographic and ion-pair
high-performance liquid chromatographic determination of Pseudoephedrine
hydrochloride and Bromhexine hydrochloride in P’ceuticals.” Ana.1987, 112, 871-874.
21.
Denise CO, Karina TV, Alma L and Revilla V, “Simultaneous
determination of Bromhexine and Amoxicillin in
pharmaceutical formulations by capillary electrophoresis.” J. Mex. Chem. Soc. 2011, 55, 79-83.
22.
Bhattacharyya E, “Estimation and validation of stability
indicating UV spectrophotometric method for the determination of Guaifenesin in presence of its degradant
products.” Int. J. Pharm. and P’ceutical
Sci.2013, 5, 262-268.
23.
Sharaf MH and
Stiff DD, “Determination of Guaifenesin in human
serum by capillary gas chromatography and electron capture detection.” J Pharm. Biomed Ana.2004, 35, 801-806.
24.
Sridharan D, “Bio
analytical method development and validation of Guaifenesin
in human plasma by liquid chromatography coupled with tandem mass
spectroscopy.”Pharm. Sci. Monitor.
2011, 2, 73-82.
25.
Ola MA, “Sensitive spectrophotometric method for quantisation of Guaifenesin and Dropropizine in their dosage forms.” Int. J.
Ana. Chem.2010,
2010, 5-10.
26.
Bankar AA,
“Spectrophotometric estimation of Guaifenesin and
Salbutamol in pure and tablet dosage form by using different methods.” Der Pharm. Chem.2013, 5,
92-97.
27.
Dubey N, Sahu S
and Shing GN, “Development
of HPLC method for simultaneous estimation of Ambroxol, Salbutamol
and Guaifenesin in single dosage form.” Ind. J.
Chem.-B. 2012, 51,
1633-1636.
28.
Walode SG, Deshpande SD and Deshpande AV,
“Stability indicating RP-HPLC method for simultaneous estimation of Salbutamol sulphate and Guaifenesin.” Der Pharm.
Sinica.2013, 4, 61-67.
29.
Senthilraja M and Giriraj P, “RP-HPLC method for the simultaneous estimation
of Terbutaline sulphate, Bromhexine hcl and Guaifenesin in cough syrup.” Asian J. P’ceutical
and Clinical Res. 2011,
4, 13-15.
30.
Nalluri BN,
“Simultaneous estimation of Phenylephrine hcl and Guaifenesin in bulk drug
and pharmaceutical dosage forms by RP-HPLC method.” J. Chem. andP’ceutical
Res.2013, 5, 188-194.
31.
Mallu UR, Bobbarala V and Penumajji S,
“Analysis of cough and analgesic range of pharmaceutical active ingredients
using RP-HPLC method.”Int. J. Pharm. and Bio Sci.2011, 2, 439-452.
32.
Harsono T, Yuwono M and Indrayanto G,
“Simultaneous determination of some active ingredients in cough and cold
preparations by gas chromatography, and method validation.” J.
AOAC Int.2005, 88,
1093-1098.
33.
Athanikar NK, “Rapid
quantitative analysis of Chlorpheniramine in plasma,
saliva and urine by high-performance liquid chromatography.” J. Chro. B:
Biomed. Sci. andAppli.1979,
162, 367–376.
34.
Subramaniyan SP and Das
SK, “Rapid identification and quantification of Chlorpheniramine
maleate or Pheniramine maleate in pharmaceutical preparations by thin-layer
chromatography-densitometry.” J. AOAC
Int.2004, 87, 1319-1322.
35.
Midha KK, “Subnanogram quantitation of Chlorpheniramine in plasma by a new radioimmunoassay and
comparison with a liquid chromatographic method.” J. P’ceutical Sci.1984, 73, 1144–1147.
36.
Sawant R,
“Simultaneous estimation and validation of Paracetamol, Phenylephrine
hcl and Chlorpheniramine maleate in tablets by spectrophotometric method.” J. P’ceutical Res.
and Health Care, 2011, 3,
23.
37.
Kaura A, ”Spectrophotometric
determination of Chlorpheniramine maleate
and Phenylpropanolamine hydrochloride in dosage
forms.” Int. Current P’ceutical J.2013,
2, 97-100.
38.
Qi ML.
“Simple HPLC method for simultaneous determination of Acetaminophen, Caffeine
and Chlorpheniramine maleate
in tablet formulations.” Chro.2002; 56, 295-298.
39.
Şenyuva H. and Ozden T, “Simultaneous high-performance liquid
chromatographic determination of Paracetamol, Phenylephrine
hcl and Chlorpheniramine maleate in pharmaceutical dosage forms.” J. Chro. Sci.2002; 40, 97-100.
40.
Maithani M,
“Development and validation of a RP-HPLC method for the determination of Chlorpheniramine maleate and Phenylephrine in pharmaceutical dosage form.” Pharm. Globale
(IJCP). 2010, 5, 1-4.
41.
Kommana R and Basappa P, “Validated stability indicating RP-HPLC method
for simultaneous estimation of Codeine phosphate and Chlorpheniramine
maleate from their combined liquid dosage form.” Chro. Res. Int.2013, 2, 7-14.
42.
Rajurkar S,
“Simultaneous determination of Chlorpheniramine maleate, Paracetamol and Pseudoephedrine hcl in pharmaceutical preparations by HPLC.” Int. J.
Life science and Pharm. Res.2011, 1, 94-100.
43.
Al-Shaalan NH, “Simultaneous
estimation of Chlorpheniramine maleate,
Dextromethorphan HBr and Phenylephrin HCl in codilar syrup using HPLC.” J. of Ph’ceuticaland Sci. Inno.
2012, 1, 29-32.
44.
RedasanI VK,
“Simultaneous determination of Chlorpheniramine maleate, Phenylephrine
hydrochloride, Paracetamol and Caffeine in pharmaceutical preparation by
RP-HPLC.” Chem. Industry and Chem.
Eng. Qua. 2013, 19,
57-65.
45. Virani P, Raj H, Jain V and Jain P. Updated
review: validation and method validation parameters. Pharma tutor, 2(10); 2014:
27-37.
Received on 04.03.2015 Accepted on 21.03.2015
© Asian Pharma
Press All Right Reserved
Asian J. Res.
Pharm. Sci. 5(2):
April-June 2015; Page 76-82
DOI: 10.5958/2231-5659.2015.00013.2